The laboratory diagnosis of antiphospholipid antibody syndrome (APS) requires the demonstration of antiphospholipid antibodies (aPL) by lupus anticoagulant (LAC) measured through coagulation assays, anticardiolipin IgG or IgM antibodies (aCL) and/or anti-beta 2-glycoprotein I IgG or IgM antibodies (anti-beta 2-GPI), usually detected by ELISA. In this study we tested aCL by a new automated system using the chemiluminescence principle. Our results showed that, while almost all the sera from APS patients, positive for IgG aCL and anti-beta 2-GPI by ELISA, were also positive for IgG aCI by chemiluminescence, only 30.13% of patients without clinical manifestations of APS, but positive for aCL and persistently negative for anti-beta 2-GPI (by ELISA) and LA, confirmed the positive test by chemiluminescence. This difference was highly significant (p<0.0001). Interestingly, this test also prompted to identify 20% of patients positive for LA, but persistently negative for both aCL and anti-beta 2-GPI IgG (ELISA). Thus, the new technology of automated chemiluminescence assay for measuring aPL may represent an useful tool to identify "true" APS patients. (C) 2012 Elsevier B.V. All rights reserved.
Detection of antiphospholipid antibodies by automated chemiluminescence assay / Capozzi, Antonella; Emanuela, Lococo; Grasso, Maria; Longo, Agostina; Garofalo, Tina; Misasi, Roberta; Sorice, Maurizio. - In: JOURNAL OF IMMUNOLOGICAL METHODS. - ISSN 0022-1759. - ELETTRONICO. - 379:1-2(2012), pp. 48-52. [10.1016/j.jim.2012.02.020]
Detection of antiphospholipid antibodies by automated chemiluminescence assay
CAPOZZI, ANTONELLA;GRASSO, MARIA;LONGO, Agostina;GAROFALO, TINA;MISASI, Roberta;SORICE, Maurizio
2012
Abstract
The laboratory diagnosis of antiphospholipid antibody syndrome (APS) requires the demonstration of antiphospholipid antibodies (aPL) by lupus anticoagulant (LAC) measured through coagulation assays, anticardiolipin IgG or IgM antibodies (aCL) and/or anti-beta 2-glycoprotein I IgG or IgM antibodies (anti-beta 2-GPI), usually detected by ELISA. In this study we tested aCL by a new automated system using the chemiluminescence principle. Our results showed that, while almost all the sera from APS patients, positive for IgG aCL and anti-beta 2-GPI by ELISA, were also positive for IgG aCI by chemiluminescence, only 30.13% of patients without clinical manifestations of APS, but positive for aCL and persistently negative for anti-beta 2-GPI (by ELISA) and LA, confirmed the positive test by chemiluminescence. This difference was highly significant (p<0.0001). Interestingly, this test also prompted to identify 20% of patients positive for LA, but persistently negative for both aCL and anti-beta 2-GPI IgG (ELISA). Thus, the new technology of automated chemiluminescence assay for measuring aPL may represent an useful tool to identify "true" APS patients. (C) 2012 Elsevier B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
